Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

References

• Cummings JL. Theories behind existing scales for rating behavior in dementia. Int Psychogeriatr 1996;8:293-300
   PubMedGoogle Scholar
• Teri L, Logsdon RG. Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. J Geriatr Psychiatry Neurol 1995;8:S8-17
   PubMed Web of Science ®Google Scholar
• Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24:98-104
   PubMed Web of Science ®Google Scholar
• Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 2009;11:20-6
   PubMed Web of Science ®Google Scholar
• Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002;127:20-36
   PubMedGoogle Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease for the ENA 713 B352 Study Group. Int J Geriatric Psychopharmacol 1998;1:55-65
   Google Scholar
• Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-8
   PubMed Web of Science ®Google Scholar
• Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: Results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-12
   PubMed Web of Science ®Google Scholar
• Bullock R, Moulias R, Steinwachs K-C, et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer’s disease. Int Psychogeriatr 2001;13:P-248
   Google Scholar
• Cummings J, Anand R, Koumaras B, et al. Rivastigmine provides behavioural benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000;54:A468
   Web of Science ®Google Scholar
• Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer’s disease and related dementias: A 26-week follow-up. Int Psychogeriatrics 2001;13:P-246
   Google Scholar
• Messina J, Koumaras B, Sohn H, et al. Treatment with rivastigmine reduces the need for psychotropic medications in patients with Alzheimer’s disease residing in long-term care facilities. Poster presented at the 3rd International Meeting of the College of Psychiatric Neurological Pharmacists, April 16--19, 2000, Washington, DC, USA
   Google Scholar
• Potkin SG, Koumaras B, Rabinowicz A, et al. Rivastigmine treatment with slow titration improves behaviors in AD. Poster presented at the American Psychogeriatric Association (APA), 2003, San Francisco, USA
   Google Scholar
• Verny M, Fremont P, Bourrin JC, et al. Reduced psychotropic drug use in patients with Alzheimer’s disease receiving rivastigmine: results of the EXELAN study. J Drug Assess 2004;7:123-32
   Google Scholar
• Gauthier S, Juby A, Morelli L, et al. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin 2006;22:2251-65
   PubMed Web of Science ®Google Scholar
• Gauthier S, Juby A, Rehel B, et al. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract 2007;61:886-95
   PubMed Web of Science ®Google Scholar
• Mets T, Vandewoude M, Jacquy J, et al. Patient and caregiver outcomes after 6 +/− 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study. Curr Med Res Opin 2007;23:2485-501
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Retz-Junginger P, et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1998;11:211-16
   PubMed Web of Science ®Google Scholar
• Cumbo E. Differential effects of rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Primary Care and Community Psychiatry 2005;10:95-102
   Google Scholar
• Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008;24:157-66
   PubMed Web of Science ®Google Scholar
• Narayanan S, Beusterien KM, Thomas SK, et al. Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc 2006;7:12-16
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-95
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, et al. The effects of donepezil in patients with Alzheimer's disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44
   PubMed Web of Science ®Google Scholar
• Raskind M, Truyen L. Galantamine has long term cognitive benefits in Alzheimer's disease – An analysis of responder rates at 36 months. Poster presented at the 7th International Geneva/Springfield symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, 2002
   Google Scholar
• Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-31
   PubMed Web of Science ®Google Scholar
• Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patters in Alzheimer disease. In Bick KL, Katzman R, Terry RD, eds. Alzheimer Disease. New York: Raven Press, 1994:263-91
   Google Scholar
• Grossberg GT. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings. Drugs Aging 2008;25:573-84
   PubMed Web of Science ®Google Scholar
• Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:83-93
   Web of Science ®Google Scholar
• Grossberg GT. The ABC of Alzheimer’s disease: behavioural symptoms and their treatment. Int Psychogeriatr 2002;14:27-49
   PubMed Web of Science ®Google Scholar
• Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007;4:277-93
   PubMed Web of Science ®Google Scholar
• Lane RM, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias. Med Hypotheses 2009;73:230-50
   PubMed Web of Science ®Google Scholar
• Potkin SG. Butyrylcholinesterase: a target in the cholinergic treatment of Alzheimer’s disease. Primary Care Psychiatr 2004;9:P1-6
   Web of Science ®Google Scholar
• Giacobini E. Butyrylcholinesterase: its role in brain function. In: Giacobini E, ed. Butyrylcholinesterase: its Function and Inhibitors. London: Martin Dunitz, 2003:1-20
   Google Scholar
• Herrmann N, Gauthier S, Lysy PG, et al. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimers Dement 2007;3:385-97
   PubMed Web of Science ®Google Scholar
• Fillit H. Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease. Neurology 2005;65:S31-3
   Web of Science ®Google Scholar
• Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002;127:45-63
   PubMedGoogle Scholar